Skip to content

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Multiple Sclerosis

To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after exposure to beta-interferon for MS.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria: Cases and controls must have

* definite MS (Poser or McDonald criteria)
* relapsing-remitting or secondary-progressive disease course
* Prescribed a beta-interferon as their immunomodulatory drug for MS

Exclusion Criteria:

* primary-progressive MS
* an elevated liver test result within 6 months of starting beta-interferon treatment
* presence of a co-morbidity that is a known risk-factor for liver injury

Lieu de l'étude

London Health Sciences Centre MS clinic
London Health Sciences Centre MS clinic
London, Ontario
Canada

Contactez l'équipe d'étude

Dalhousie MS Research Unit
Dalhousie MS Research Unit
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

MS Clinic UBC Hospital
MS Clinic UBC Hospital
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Hôpital Notre-Dame MS clinic
Hôpital Notre-Dame MS clinic
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Winnipeg Health Sciences Centre
Winnipeg Health Sciences Centre
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of British Columbia
Participants recherchés
Plus d'informations
ID de l'étude: NCT01118130